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PACUTE MYOCARDIAL INFARCTION
When Is Door-to-Balloon Time Critical?
Analysis From the HORIZONS-AMI (Harmonizing Outcomes with
Revascularization and Stents in Acute Myocardial Infarction) and
CADILLAC (Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications) Trials
Bruce R. Brodie, MD,* Bernard J. Gersh, MB, CHB, DPHIL,† Thomas Stuckey, MD,*
Bernhard Witzenbichler, MD,‡ Giulio Guagliumi, MD,§ Jan Z. Peruga, MD, Dariusz Dudek, MD,¶
Cindy L. Grines, MD,# David Cox, MD,** Helen Parise, SCD,†† Abhiram Prasad, MD,†
Alexandra J. Lansky, MD,†† Roxana Mehran, MD,†† Gregg W. Stone, MD††
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Objectives Our objective was to evaluate the impact of door-to-balloon time (DBT) on mortality depending on clinical risk
and time to presentation.
Background DBT affects the mortality rate in ST-segment elevation myocardial infarction treated with primary percutaneous
coronary intervention, but the impact may vary across subgroups.
Methods The CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) and
HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trials
evaluated stent and antithrombotic therapy in patients undergoing primary percutaneous coronary intervention.
We studied the impact of DBT on mortality in 4,548 patients based on time to presentation and clinical risk.
Results The 1-year mortality rate was lower in patients with short versus long DBT (90 min vs. 90 min, 3.1% vs.
4.3%, p  0.045). Short DBTs were associated with a lower mortality rate in patients with early presentation
(90 min: 1.9% vs. 3.8%, p  0.029) but not those with later presentation (90 min: 4.0% vs. 4.6%, p  0.47).
Short DBTs showed similar trends for a lower mortality rate in high-risk (5.7% vs. 7.4%, p  0.12) and low-risk
(1.1% vs. 1.6%, p  0.25) patients. Short DBTs had similar relative risk reductions in patients with early presen-
tation in high-risk (3.7% vs. 7.0%, p  0.08) and low-risk (0.8% vs. 1.5%, p  0.32) patients, although the abso-
lute benefit was greatest in high-risk patients.
Conclusions Short DBTs (90 min) are associated with a lower mortality rate in patients with early presentation but have
less impact on the mortality rate in patients presenting later. The absolute mortality rate reduction with short
DBT is greatest in high-risk patients presenting early. These data may be helpful in designing triage strategies
for reperfusion therapy in patients presenting to non–percutaneous coronary intervention hospitals. (J Am Coll
Cardiol 2010;56:407–13) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.020c
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When Is Door-to-Balloon Time Critical? July 27, 2010:407–13most in patients presenting early
after the onset of symptoms and
in patients at high clinical risk,
but the data are limited and con-
flicting (2,3). Improved under-
standing of how delays in DBT
affect the mortality rate in sub-
groups may help in triaging
STEMI patients presenting at
non-PCI hospitals.
The purpose of this study was to
evaluate the impact of delays in
BT on mortality in patients with early versus late presenta-
ion and in patients with high and low clinical risk from the
ADILLAC (Controlled Abciximab and Device Investiga-
ion to Lower Late Angioplasty Complications) and
ORIZONS-AMI (Harmonizing Outcomes with Revascu-
arization and Stents in Acute Myocardial Infarction) trials
4,5).
ethods
tudy population. The CADILLAC trial evaluated abcix-
mab and coronary stenting and the HORIZONS-AMI
rial evaluated bivalirudin and drug-eluting stents in
TEMI patients undergoing primary PCI (4,5). The cur-
ent study population included all patients randomized in
aseline Variables by Door-to-Balloon TimeTable 1 Baseline Variables by Door-to-Balloon Time
Door-to-Balloon Time
p Value
<90 min
(n  1,611)
>90 min
(n  2,937)
Clinical variables
Age, yrs 60.1 (11.8) 60.3 (12.0) 0.62
Age 65 yrs 35.1% 35.8% 0.64
Age 75 yrs 12.5% 13.5% 0.35
Female 22.7% 26.1% 0.011
Diabetes 14.6% 17.0% 0.032
Prior infarction 10.1% 12.6% 0.012
Anterior infarction 40.1% 40.0% 0.92
Killip class II to IV 8.8% 10.1% 0.16
Weight, kg 81.6 (15.4) 82.6 (16.4) 0.058
Weight 67 kg 15.9% 15.3% 0.58
Time to presentation 90 min 41.1% 42.0% 0.55
TIMI risk score 1.7 (1.6) 1.8 (1.7) 0.19
Angiographic variables
Infarct artery location
Left anterior descending 40.1% 40.0% 0.98
Circumflex 16.2% 18.6% 0.042
Right coronary artery 46.9% 44.4% 0.10
Left main 0.3% 0.1% 0.23
3-vessel disease 17.5% 19.8% 0.061
Index LVEF, % 58.1 (12.7) 57.8 (12.8) 0.62
Index LVEF 40% 9.5% 9.7% 0.31
TIMI flow grade 2 to 3 pre-PCI 27.9% 37.7% 0.0001
alues are mean (SD) or percent.
Abbreviations
and Acronyms
DBT  door-to-balloon time
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctiont
LVEF  left ventricular ejection fraction; PCI  percutaneous coronary infarction; TIMI 
hrombolysis In Myocardial Infarction.hese trials who underwent primary PCI and had DBT data
vailable (n  4,548).
efinitions. DBT was the time from hospital arrival until
alloon inflation. Time to presentation was the time from
ymptom onset until arrival at the first hospital. Clinical risk
as assessed using a modified Thromobolysis In Myocardial
nfarction (TIMI) risk score (6). Selected variables were
ssigned points weighted as follows: age 75 years and older
3 points), age 65 years and older (2 points), Killip class II
o IV (2 points), anterior infarction (1 point), diabetes (1
oint), weight67 kg (1 point), and these were summed for
ach patient to give a modified TIMI risk score.
tatistical analyses. Baseline categorical variables were
ompared using chi-square testing, and continuous variables
ere compared using t tests. Mortality rates at 1 year were
etermined by Kaplan-Meier estimates, and comparisons
etween categories of DBT were performed with univariate
nd multivariate Cox regression analyses. In the multivariate
ox regression models, all clinical variables in Tables 1 and 2
ere entered into the models.
esults
edian time to presentation was 112 min (interquartile
ange 60 to 205 min) and median DBT, including both
ransferred and nontransferred patients, was 107 min (in-
aseline Variables by Time to PresentationTable 2 Baseline Variables by Time to Presentation
Time to Presentation
p Value
<90 min
(n  1,917)
>90 min
(n  2,700)
Clinical variables
Age, yrs 58.4 (11.7) 61.6 (11.9) 0.0001
Age 65 yrs 29.6% 40.2% 0.0001
Age 75 yrs 10.1% 15.2% 0.0001
Female 21.1% 27.2% 0.0001
Diabetes 12.9% 18.3% 0.0001
Prior infarction 12.8% 11.0% 0.064
Anterior infarction 41.6% 38.9% 0.07
Killip class II to IV 9.1% 10.0% 0.32
Weight, kg 83.4 (16.3) 81.5 (15.9) 0.0001
Weight 67 kg 14.1% 16.6% 0.02
TIMI risk score 1.6 (1.6) 1.9 (1.7) 0.0001
Angiographic variables
Infarct artery location
Left anterior descending 41.4% 39.1% 0.11
Circumflex 16.3% 18.8% 0.029
Right coronary artery 45.2% 45.2% 0.97
Left main 0.1% 0.2% 0.34
3-vessel disease 16.5% 21.2% 0.0001
Index LVEF, % 58.2 (12.6) 57.9 (12.7) 0.46
Index LVEF 40% 8.5% 9.4% 0.44
TIMI flow grade 2 to 3 pre-PCI 35.2% 33.6% 0.25
alues are mean (SD) or percentage.
Abbreviations as in Table 1.erquartile range 79 to 146 min).
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July 27, 2010:407–13 When Is Door-to-Balloon Time Critical?aseline variables by DBT and time to presentation.
he frequency of female sex, diabetes, and previous
nfarction was higher in patients with long versus short
BT (Table 1).
Patients with late versus early time to presentation were
lder, more often female, and more often diabetic; weighed
ess; and had a higher modified TIMI risk score (Table 2).
ut-point analyses. On the basis of previous experiences
1–3), comparisons of mortality with short versus long DBT
ere assessed at cut points of 60, 90, and 120 min. A cut
Figure 1 DBT and 1-Year Mortality Rate
Kaplan-Meier estimates for mortality rate in ST-segment elevation myocardial infar
ut-Point Analyses for DBT, Time to Presentation, and TIMI Risk STable 3 Cut-Point Analyses for DBT, Time to Presentation, and
1-Year Mortality (%)*
DBT cut points Short DBT Lon
60 min 3.0
90 min 3.1
120 min 3.7
Time to presentation cut points DBT 90 min DBT
60 min (n  1,122) 2.3
60 min (n – 3,327) 3.4
90 min (n  1,853) 1.9
90 min (n  2,596) 4.0
120 min (n  2,472) 2.4
120 min (n  1,977) 4.0
Modified TIMI risk cut points DBT 90 min DBT
TIMI risk score 2 (n  2,402) 1.1
TIMI risk score 2 (n  2,047) 5.7
TIMI risk score 3 (n  3,067) 1.4
TIMI risk score 3 (n  1,382) 7.2
TIMI risk score 4 (n  3,738) 2.0
TIMI risk score 4 (n  711) 9.7 1
1-year mortalities are Kaplan-Meier estimates. †Hazard ratios are unadjusted and compare mor
CI  confidence interval; other abbreviations as in Table 1.oint of 90 min gave the lowest hazard ratio (HR) for
ortality comparing short and long DBTs (Table 3).
Comparisons of mortality by DBT in patients with early
ersus late time to presentation were assessed at time to
resentation cut points of 60, 90, and 120 min (2,3). A cut
oint of 90 min resulted in the greatest difference in HRs
or mortality rate with short versus long DBTs between
atients with early and late presentation (Table 3).
Comparisons of mortality by DBT in patients at low and
igh clinical risk were assessed at TIMI risk score cut points
atients with a door-to-balloon time (DBT) of 90 min versus 90 min.
Risk Score
Hazard Ratio† 95% CI p Value
0.75 0.45–1.22 0.25
0.72 0.52–0.99 0.045
0.87 0.65–1.16 0.35
in
0.68 0.31–1.52 0.34
0.73 0.51–1.05 0.09
0.49 0.26–0.93 0.029
0.86 0.58–1.28 0.47
0.69 0.42–1.14 0.15
0.76 0.49–1.19 0.24
in
0.64 0.30–1.37 0.25
0.75 0.51–1.02 0.12
0.65 0.36–1.18 0.16
0.78 0.52–1.14 0.20
0.73 0.46–1.15 0.17
0.75 0.47–1.19 0.22
ith short versus long door-to-balloon times (DBTs).ction pcoreTIMI
g DBT
4.0
4.3
4.1
90 m
3.3
4.6
3.8
4.6
3.5
5.2
90 m
1.6
7.4
2.1
9.0
2.5
3.1
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When Is Door-to-Balloon Time Critical? July 27, 2010:407–13f 2, 3, and 4. All cut points demonstrated similar HRs for
igh- and low-risk groups (Table 3).
mpact of DBT on 1-year mortality by time to presentation
nd TIMI risk score. In the entire cohort, short DBTs
90 min) were associated with significantly lower mortality
ates (3.1% vs. 4.3%, HR: 0.72, 95% confidence interval [CI]:
.52 to 0.99, p  0.045) (Table 3, Fig. 1). After adjusting for
ifferences in baseline variables, study differences, and treat-
ent assignment, the differences were not quite significant
HR: 0.72, 95% CI: 0.52 to 1.01, p  0.058).
Figure 2 DBT and 1-Year Mortality Rate in Early and Late Pres
Kaplan-Meier estimates for mortality comparing door-to-balloon time (DBT) of 90
in patients with time to presentation 90 min (A) and in patients with time to preIn patients with early time to presentation (90 min),
hort DBTs (90 min) were associated with lower mortal-
ty rate (1.9% vs. 3.8%, HR: 0.49, 95% CI: 0.26 to 0.93,
 0.029), whereas in patients with late time to presenta-
ion (90 min), the DBT had no significant impact on the
ortality rate (4.0% vs. 4.6%, HR: 0.86, 95% CI: 0.58 to 1.28,
 0.47) (p value for interaction  0.14) (Table 3, Fig. 2).
he impact of short DBTs on patients with early presentation
emained significant after adjusting for differences in baseline
ariables (HR: 0.51, 95% CI: 0.26 to 0.98, p  0.044).
s
rsus 90 min
ion 90 min (B).enter
min ve
sentat
r
T
(
m
t
m
w
a
r
p
s
(
D
T
a
411JACC Vol. 56, No. 5, 2010 Brodie et al.
July 27, 2010:407–13 When Is Door-to-Balloon Time Critical?The HRs of short and long DBTs for 1-year mortality
ate were similar in high- and low-risk patients (modified
IMI risk score 2 vs. 2) (p value for interaction  0.71)
Table 3, Fig. 3). However, the absolute reduction in
ortality rate with short DBTs was greater in high-risk
han low-risk patients (1.7% vs. 0.5%) (Table 3).
In patients presenting early (90 min), the HRs for
ortality rate in patients with short versus long DBTs
ere identical for high- versus low-risk patients, but the
Figure 3 DBT and 1-Year Mortality Rate in Low- and High-Risk
Kaplan-Meier estimates for mortality comparing door-to-balloon time (DBT) of 90
(modified Thrombolysis In Myocardial Infarction [TIMI] risk score 2) (A) and in pabsolute mortality rate differences were greater in high- pisk patients (3.3% vs. 0.7%) (Table 4, Fig. 4). In patients
resenting late (90 min), mortality was similar with
hort and long DBTs in both high- and low-risk patients
Table 4).
iscussion
he major finding of this study is that short DBTs (90 min)
re associated with a lower 1-year mortality rate in patients
nts
rsus 90 min in patients at low risk
at high risk (modified TIMI risk score 2) (B).Patie
min ve
tientsresenting early after the onset of symptoms but appear to have
l
s
w
h
r
b
(
o
3
c
2
o
b
s
t
s
p
412 Brodie et al. JACC Vol. 56, No. 5, 2010
When Is Door-to-Balloon Time Critical? July 27, 2010:407–13ess impact on the mortality rate in patients presenting later. A
econd finding of our study is that short DBTs are associated
ith similar relative reductions in mortality rate in low- and
igh-risk patients, although the absolute reduction in mortality
ate is greatest in high-risk patients.
These data are consistent with the mechanism of
enefit of reperfusion therapy described by Gersh et al.
7), which states that the greatest benefit of reperfusion
ccurs when reperfusion is achieved within the first 2 to
Figure 4 DBT and 1-Year Mortality Rate in Low- and High-Risk
Kaplan-Meier estimates for mortality comparing DBT of 90 min versus 90 min
patients at low risk (modified TIMI risk score 2) (A) and in patients at high risk (h, during which time incremental delays result in considerable loss of myocardial salvage and survival. After
to 3 h, incremental delays have much less impact on
utcomes. Accordingly, short DBTs should be most
eneficial in patients presenting early after the onset of
ymptoms when reperfusion can be achieved within the
ime window of maximal benefit.
Data regarding this are conflicting. A large single-center
tudy found improved survival with short DBTs in patients
resenting early but not in patients presenting later (2). In
nts Presenting Early
ents with time to presentation 90 min in
ed TIMI risk score 2) (B). Abbreviations as in Figure 3.Patie
in pati
modifiontrast, a large registry found that short DBTs were
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July 27, 2010:407–13 When Is Door-to-Balloon Time Critical?ssociated with a lower mortality rate in patients with both
arly and late presentation (3). Hidden biases in registries
or patients with long DBTs to have higher mortality may
xplain the differences between the registry data and the
resent study.
linical implications. Pinto et al. (8) found that the
CI-related delay at which primary PCI loses its advantage
ver fibrinolytic therapy was shorter in patients presenting
arly versus later and in anterior versus nonanterior infarc-
ion. These data and our data suggest that patients present-
ng early (and patients at high clinical risk) may benefit from
lternative reperfusion strategies such as fibrinolysis or
acilitated PCI. Facilitated PCI strategies have not yet
hown any advantage over primary PCI, but a retrospective
nalysis of the FINESSE (Facilitated INtervention with
nhanced Reperfusion Speed to Stop Events) trial found
hat high-risk patients presenting early at spoke hospitals
ad better outcomes with facilitated PCI compared with
rimary PCI (9–11). It remains to be proven whether
acilitated PCI might be beneficial in high-risk STEMI
atients presenting early after the onset of symptoms.
tudy limitations. This is an observational, post hoc anal-
sis of data from 2 randomized trials. We believe that this is
representative group of the overall STEMI population,
ut we do not have data on patients who were screened but
ot enrolled to document this. Also, exclusion of patients
ecause of missing DBT data could potentially affect our
esults.
In analyzing numerous cut points, there is the potential
or false-positive results. However, our cut points were
ased on clinical considerations, which should minimize
his error.
Although this is the largest randomized primary PCI
atabase evaluating DBT, the power to detect differences in
ortality rate in subgroups is limited. This may be the
eason why the adjusted differences in mortality rate be-
ween short and long DBTs and the interaction between
ime to presentation and DBT on mortality rate were not
uite significant.
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-Year Mortality Rate by DBT, Time to Presentation, and TIMI RiskTable 4 1-Year Mortality Rate by DBT, Time to Presentation, a
1-Year Mortality (%)*
DBT <90 min DBT
Time to presentation 90 min
TIMI risk score 2 (n  1,102) 0.8
TIMI risk score 2 (n  751) 3.7
Time to presentation 90 min
TIMI risk score 2 (n  1,300) 1.3
TIMI risk score 2 (n  1,296) 6.8
1-year mortalities are Kaplan-Meier estimates. †Hazard ratios are unadjusted and compare mor
Abbreviations as in Tables 1 and 3.f the manuscript. peprint requests and correspondence: Dr. Bruce R. Brodie, 313
eadowbrook Terrace, Greensboro, North Carolina 27408. E-mail:
brodie@triad.rr.com.
EFERENCES
1. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of
symptom-onset-to-balloon time and door-to-balloon time with mor-
tality in patients undergoing angioplasty for acute myocardial infarc-
tion. JAMA 2000;283:2941–7.
2. Brodie BR, Hansen C, Stuckey TD, et al. Door-to-balloon time with
primary percutaneous coronary intervention for acute myocardial
infarction impacts late cardiac mortality in high-risk patients and
patients presenting early after the onset of symptoms. J Am Coll
Cardiol 2006;47:289–95.
3. McNamara RL, Wang Y, Herrin J, et al. Effect of door-to-balloon
time on mortality in patients with ST-segment elevation myocardial
infarction. J Am Coll Cardiol 2006;47:2180–6.
4. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty
with stenting, with or without abciximab, in acute myocardial infarc-
tion. N Engl J Med 2002;346:957–66.
5. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during
primary PCI in acute myocardial infarction. N Engl J Med 2008;358:
2218–30.
6. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for
ST-elevation myocardial infarction: a convenient, bedside, clinical
score for risk assessment at presentation. An intravenous nPA for
treatment of infarcting myocardium early II Trial substudy. Circula-
tion 2000;102:2031–7.
7. Gersh BJ, Stone GW, White HD, Holmes DR. Pharmacological
facilitation of primary percutaneous coronary intervention for acute
myocardial infarction. Is the slope of the curve the shape of the future?
JAMA 2005;293:979–86.
8. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in
reperfusion for ST-elevation myocardial infarction. Implications when
selecting a reperfusion strategy. Circulation 2006;114:2019–25.
9. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated
percutaneous coronary intervention in patients with ST-segment
elevation acute myocardial infarction (ASSENT-4 PCI) randomized
trial. Lancet 2006;367:569–78.
0. Ellis SG, Tendera M, de Belder MA, et al., for the FINESSE
Investigators. Facilitated PCI in patients with ST-elevation myocar-
dial infarction. N Engl J Med 2008;358:2205–17.
1. Herrmann HC, Lu J, Brodie BR, et al., for the FINESSE Investiga-
tors. Benefit of facilitated PCI in high risk ST-elevation myocardial
infarction patients presenting to non-PCI hospitals. J Am Coll Cardiol
Intv 2009;2:917–24.
ey Words: door-to-balloon time y myocardial infarction y primary
eMI Risk Score
Hazard Ratio† 95% CI p Valuein
0.52 0.14–1.89 0.32
0.52 0.24–1.08 0.08
0.76 0.29–2.00 0.58
0.88 0.57–.35 0.57
ith short versus long DBTs.Scornd TI
>90 m
1.5
7.0
1.7
7.6ercutaneous coronary intervention.
